Status and phase
Conditions
Treatments
About
This study is a randomized, double-blind, multi-center phase III clinical study to compare the efficacy and safety of penpulimab combined with chemotherapy and placebo combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
278 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Zhifang Yao, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal